ADAMIS ANTHONY P 4

What Happened
Anthony P. Adamis, a director of Kalaris Therapeutics, reported receiving a derivative award (option grant) for 9,000 shares on June 3, 2026. The filing shows an acquisition price of $0.00 and a reported value of $0 for the grant (common for option awards when reported as a derivative instrument). This is an award/compensation grant, not an open-market purchase or sale.

Key Details

• Transaction date: June 3, 2026 (Form 4 filed June 4, 2026) — appears to be filed timely.
• Transaction code: A (Grant/award/other acquisition).
• Shares/units: 9,000 (derivative securities — option grant).
• Reported price/value: $0.00 / $0 (as reported on Form 4).
• Vesting: The option vests in full on the earlier of (i) June 3, 2027 or (ii) the issuer’s 2027 Annual Meeting of Stockholders, subject to continued service (footnote F1).
• Shares owned after transaction: not disclosed in the provided filing summary.

Context

• This transaction is a grant of a derivative instrument (an option award) rather than a stock purchase or sale. The filing does not indicate exercise or sale; it documents the grant and its vesting schedule.
• Such equity awards are typically part of director compensation and do not by themselves signal a buy/sell decision by the insider.